Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fuyong Du

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Experimental Physiology|October 21, 2006
A slowly inactivating sodium current (INa2) in the plateau range in canine cardiac Purkinje single cellsMario Vassalle, Leonardo Bocchi, Fuyong Du
Biomarker Research|November 21, 2013
Metabolomic analyses for atherosclerosis, diabetes, and obesityFuyong Du, Anthony Virtue, Hong Wang, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|April 27, 2023
Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous ThrombosisXinkang Wang, Qiu Li, Fuyong Du, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 28, 2019
Pharmacological Profile of JNJ-64179375: A Novel, Long-Acting Exosite-1 Thrombin InhibitorZheng Huang Devine, Fuyong Du, Qiu Li, et al.
Cardiovascular Research|June 14, 2002
Effects of partial ischaemia and volume loading on myocardial efficiency and cardiac performance in dogsGuangping Li, Xu Wang, Fuyong Du, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitorsGuozhang Xu, Fuyong Du, Gee-Hong Kuo, et al.
Frontiers in Bioscience (Landmark Edition)|June 2, 2012
Endothelial progenitor cells in atherosclerosisFuyong Du, Jun Zhou, Ren Gong, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2017
Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonistsXuqing Zhang, Zhihua Sui, Jack Kauffman, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 DiabetesXuqing Zhang, Mark Wall, Zhihua Sui, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2019
Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetesGuozhang Xu, Michael D Gaul, Fengbin Song, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Experimental Physiology|October 21, 2006
A slowly inactivating sodium current (INa2) in the plateau range in canine cardiac Purkinje single cellsMario Vassalle, Leonardo Bocchi, Fuyong Du
Biomarker Research|November 21, 2013
Metabolomic analyses for atherosclerosis, diabetes, and obesityFuyong Du, Anthony Virtue, Hong Wang, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|April 27, 2023
Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous ThrombosisXinkang Wang, Qiu Li, Fuyong Du, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 28, 2019
Pharmacological Profile of JNJ-64179375: A Novel, Long-Acting Exosite-1 Thrombin InhibitorZheng Huang Devine, Fuyong Du, Qiu Li, et al.
Cardiovascular Research|June 14, 2002
Effects of partial ischaemia and volume loading on myocardial efficiency and cardiac performance in dogsGuangping Li, Xu Wang, Fuyong Du, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitorsGuozhang Xu, Fuyong Du, Gee-Hong Kuo, et al.
Frontiers in Bioscience (Landmark Edition)|June 2, 2012
Endothelial progenitor cells in atherosclerosisFuyong Du, Jun Zhou, Ren Gong, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2017
Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonistsXuqing Zhang, Zhihua Sui, Jack Kauffman, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 DiabetesXuqing Zhang, Mark Wall, Zhihua Sui, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2019
Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetesGuozhang Xu, Michael D Gaul, Fengbin Song, et al.
Pageof 3